No abstract available
MeSH terms
-
Administration, Oral
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Clinical Trials, Phase III as Topic
-
Combined Modality Therapy
-
Dacarbazine / administration & dosage
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives
-
Disease-Free Survival
-
Dose-Response Relationship, Drug
-
Gemcitabine
-
Humans
-
Hyperthermia, Induced / instrumentation
-
Hyperthermia, Induced / methods*
-
Indazoles
-
Multimodal Imaging*
-
Neoadjuvant Therapy
-
Positron-Emission Tomography*
-
Pyrimidines / administration & dosage
-
Randomized Controlled Trials as Topic
-
Sarcoma / diagnosis
-
Sarcoma / mortality
-
Sarcoma / pathology
-
Sarcoma / therapy*
-
Sirolimus / administration & dosage
-
Sirolimus / analogs & derivatives
-
Soft Tissue Neoplasms / diagnosis
-
Soft Tissue Neoplasms / mortality
-
Soft Tissue Neoplasms / pathology
-
Soft Tissue Neoplasms / therapy*
-
Sulfonamides / administration & dosage
-
Tomography, X-Ray Computed*
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Indazoles
-
Pyrimidines
-
Sulfonamides
-
Deoxycytidine
-
ridaforolimus
-
Dacarbazine
-
pazopanib
-
Sirolimus
-
Gemcitabine